Case studies of the hepatitis B patient: A panel discussion

John M. Vierling, Lewis W. Teperman, John R. Lake, Robert P. Perrillo, Marion Peters, Michael Fried, Eugene R Schiff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In recent years, there have been significant advances in the treatment of patients with hepatitis B who are candidates for liver transplantation. This includes the prevention and management of hepatitis B posttransplantation. However, there is no established protocol for treating these patients. Ultimately, the goal would be to have patients HBV-DNA negative pretransplantation and then to prevent HBV recurrence posttransplantation to help ensure their quality of life. Several clinical case scenarios are presented and possible treatment solutions have been suggested. The timing of a transplant is critical due to the risk of viral mutation while the patient is on a nucleoside analogue antiviral agent and waiting for an organ. One successful option might be to start therapy pretransplant and continue it posttransplant. Combination therapy appears to provide the most effective course of treatment. This should include a nucleoside analogue and patients should be covered with hepatitis B immune globulin throughout the course of therapy. Several other variations of combination therapy are discussed, but many clinical issues remain to be resolved. Guidelines for future studies designed to answer these questions are proposed.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalSeminars in Liver Disease
Volume20
Issue number1 SUPPL.
StatePublished - Jul 12 2000

Fingerprint

Hepatitis B
Nucleosides
Therapeutics
Liver Transplantation
Antiviral Agents
Immunoglobulins
Quality of Life
Guidelines
Transplants
Recurrence
Mutation
DNA

Keywords

  • Case studies
  • Hepatitis B
  • Liver transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

Vierling, J. M., Teperman, L. W., Lake, J. R., Perrillo, R. P., Peters, M., Fried, M., & Schiff, E. R. (2000). Case studies of the hepatitis B patient: A panel discussion. Seminars in Liver Disease, 20(1 SUPPL.), 29-35.

Case studies of the hepatitis B patient : A panel discussion. / Vierling, John M.; Teperman, Lewis W.; Lake, John R.; Perrillo, Robert P.; Peters, Marion; Fried, Michael; Schiff, Eugene R.

In: Seminars in Liver Disease, Vol. 20, No. 1 SUPPL., 12.07.2000, p. 29-35.

Research output: Contribution to journalArticle

Vierling, JM, Teperman, LW, Lake, JR, Perrillo, RP, Peters, M, Fried, M & Schiff, ER 2000, 'Case studies of the hepatitis B patient: A panel discussion', Seminars in Liver Disease, vol. 20, no. 1 SUPPL., pp. 29-35.
Vierling JM, Teperman LW, Lake JR, Perrillo RP, Peters M, Fried M et al. Case studies of the hepatitis B patient: A panel discussion. Seminars in Liver Disease. 2000 Jul 12;20(1 SUPPL.):29-35.
Vierling, John M. ; Teperman, Lewis W. ; Lake, John R. ; Perrillo, Robert P. ; Peters, Marion ; Fried, Michael ; Schiff, Eugene R. / Case studies of the hepatitis B patient : A panel discussion. In: Seminars in Liver Disease. 2000 ; Vol. 20, No. 1 SUPPL. pp. 29-35.
@article{ff20b9f5efb34a29b1184ca55c8b1d7e,
title = "Case studies of the hepatitis B patient: A panel discussion",
abstract = "In recent years, there have been significant advances in the treatment of patients with hepatitis B who are candidates for liver transplantation. This includes the prevention and management of hepatitis B posttransplantation. However, there is no established protocol for treating these patients. Ultimately, the goal would be to have patients HBV-DNA negative pretransplantation and then to prevent HBV recurrence posttransplantation to help ensure their quality of life. Several clinical case scenarios are presented and possible treatment solutions have been suggested. The timing of a transplant is critical due to the risk of viral mutation while the patient is on a nucleoside analogue antiviral agent and waiting for an organ. One successful option might be to start therapy pretransplant and continue it posttransplant. Combination therapy appears to provide the most effective course of treatment. This should include a nucleoside analogue and patients should be covered with hepatitis B immune globulin throughout the course of therapy. Several other variations of combination therapy are discussed, but many clinical issues remain to be resolved. Guidelines for future studies designed to answer these questions are proposed.",
keywords = "Case studies, Hepatitis B, Liver transplantation",
author = "Vierling, {John M.} and Teperman, {Lewis W.} and Lake, {John R.} and Perrillo, {Robert P.} and Marion Peters and Michael Fried and Schiff, {Eugene R}",
year = "2000",
month = "7",
day = "12",
language = "English",
volume = "20",
pages = "29--35",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Case studies of the hepatitis B patient

T2 - A panel discussion

AU - Vierling, John M.

AU - Teperman, Lewis W.

AU - Lake, John R.

AU - Perrillo, Robert P.

AU - Peters, Marion

AU - Fried, Michael

AU - Schiff, Eugene R

PY - 2000/7/12

Y1 - 2000/7/12

N2 - In recent years, there have been significant advances in the treatment of patients with hepatitis B who are candidates for liver transplantation. This includes the prevention and management of hepatitis B posttransplantation. However, there is no established protocol for treating these patients. Ultimately, the goal would be to have patients HBV-DNA negative pretransplantation and then to prevent HBV recurrence posttransplantation to help ensure their quality of life. Several clinical case scenarios are presented and possible treatment solutions have been suggested. The timing of a transplant is critical due to the risk of viral mutation while the patient is on a nucleoside analogue antiviral agent and waiting for an organ. One successful option might be to start therapy pretransplant and continue it posttransplant. Combination therapy appears to provide the most effective course of treatment. This should include a nucleoside analogue and patients should be covered with hepatitis B immune globulin throughout the course of therapy. Several other variations of combination therapy are discussed, but many clinical issues remain to be resolved. Guidelines for future studies designed to answer these questions are proposed.

AB - In recent years, there have been significant advances in the treatment of patients with hepatitis B who are candidates for liver transplantation. This includes the prevention and management of hepatitis B posttransplantation. However, there is no established protocol for treating these patients. Ultimately, the goal would be to have patients HBV-DNA negative pretransplantation and then to prevent HBV recurrence posttransplantation to help ensure their quality of life. Several clinical case scenarios are presented and possible treatment solutions have been suggested. The timing of a transplant is critical due to the risk of viral mutation while the patient is on a nucleoside analogue antiviral agent and waiting for an organ. One successful option might be to start therapy pretransplant and continue it posttransplant. Combination therapy appears to provide the most effective course of treatment. This should include a nucleoside analogue and patients should be covered with hepatitis B immune globulin throughout the course of therapy. Several other variations of combination therapy are discussed, but many clinical issues remain to be resolved. Guidelines for future studies designed to answer these questions are proposed.

KW - Case studies

KW - Hepatitis B

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033917297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033917297&partnerID=8YFLogxK

M3 - Article

C2 - 10895442

AN - SCOPUS:0033917297

VL - 20

SP - 29

EP - 35

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1 SUPPL.

ER -